BrightPath Biotherapeutics Signs a Research and License Agreement with Artisan Bio to Advance Allogeneic iPSC Derived Cell Therapy Platform across Multiple Indications
Shots:
- Artisan to receive up front, license fees, research milestones for the development of CRISPR guides for the editing of BrightPath's iNKT cells & is also eligible for development milestones, net sales milestones along with royalty on future products
- BrightPath to receive non-exclusive rights to Artisan's STAR-CRISPR editing platform & accelerate the development of BrightPath's invariant natural killer T (iNKT) cells
- The collaboration focuses to develop BrightPath's iNKT cell therapy program for a range of indications, incl. solid tumors using Artisan's STAR-CRISPR system, and their leading editing efficiencies in iPSC cells. Additionally, high-throughput CRISPR editing is used by Artisan's SyionAI platform for novel drug discovery
Ref: PR Newswire | Image: BrightPath Biotherapeutics
Click here to read the full press release
Tags
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
